News zum Sektor Gesundheit aus Hong Kong (China)

 

Hong Kong Exchanges and Clearing (HKEX) will add 10 companies – including autonomous-driving firms Pony AI and WeRide – to its Tech 100 Index as part of a quarterly reshuffle that increases the benchmark's exposure to artificial intelligence and other emerging technologies. Other additions include AI drug-discovery specialist Insilico Medicine, printed-circuit-board maker Victory Giant Technology, enterprise AI company Beijing Haizhi Technology and AI data-intelligence provider Mininglamp......

CSPC PHARMA (01093.HK) announced that the SYH2092 injection developed by the group has been approved by the National Medical Products Administration of China to commence clinical trials in China.The product is an amylin receptor agonist. By optimizing agonist activity, the product is expected to improve efficacy while maintainin......

NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / JRM Construction Management completed the transformation of 54,700 square feet of prime commercial space at One Penn Plaza into a cutting-edg......

FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of Invesco Ltd. discloser: (b) Owner or   controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

GRAND PHARMA (00512.HK) announced its interim results for the six months ended June. Revenue rose 3.2% YoY to HKD6.389 billion, while gross profit fell 7.8% to HKD3.368 billion. Net profit amounted to HKD1.062 billion, down 11% YoY, with EPS at HKD0.3031. No dividend was declared. (d)~AASTOCKS Financial NewsWebsite: www.aastocks......

CSPC PHARMA (01093.HK) announced that SYS 6090 (JMT108), a first-in-class PD-1/ IL-15 bispecific fusion protein developed by the group, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastati......

CSPC PHARMA (01093.HK) announced that the Phase III clinical study of SYS 6010 developed by the group recently achieved the preset primary endpoint of progression-free survival after review and assessment by the Independent Data Monitoring Committee. The study evaluated the product as a monotherapy versus platinum-containing che......

CSPC PHARMA (01093.HK) announced that SYS 6057, a Class 1 preventive biological product and recombinant respiratory syncytial virus vaccine developed by the group, has received approval from the US Food and Drug Administration (FDA) to commence clinical trials in the United States. Previously, SYS 6057 had already obtained appro......

At close, HSI dropped 6 pts or 0.0% to 25,511. HSTI dropped 5 pts or 0.1% to 4,588. HSCEI fell 25 pts or 0.3% to 8,445. Market turnover reached $254.08 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $77.2, down 6.7%BABA (09988.HK) closed at $114.2, up 1.5%TENCENT (00700.HK) closed at $442, up 0.5%XIAOMI (01810.HK) clos......

BOCOM International issued a report saying that HENGRUI PHARMA (01276.HK)'s existing business came under pressure in the first half, while innovative drugs maintained solid growth. The company's revenue for the first half fell 2% YoY to RMB15.46 billion, of which product sales rose 2%. Revenue from innovative drugs increased 16%......

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing....

Envista , Reliance, The Ensign, The Hanover Insurance and Lenovo have been highlighted in this Screen of The Week article....

G Sachs published a research report stating that driven by licensing fee income of about RMB5.7 billion, CSPC PHARMA (01093.HK)'s 2Q revenue surged 94% YoY, while finished drug sales grew 16% YoY, accelerating from 6% growth in 1Q. Net profit jumped 389% YoY. Excluding the licensing fee income recognized in 2Q, core earnings wer......

UBS published a research report stating that CSPC PHARMA (01093.HK)'s revenue for 1H26 increased 40% YoY, while net profit rose 139%, in line with the earlier profit alert. Growth in licensing fee income and finished drug sales was slightly above guidance. In 2Q26 alone, finished drug sales increased 15.9% YoY and rose 0.2% QoQ,......

Citi said in a report that CSPC PHARMA (01093.HK)'s net profit attributable for 1H26 was RMB6.1 billion, up 139% YoY, at the high end of its profit alert range. Revenue rose 40% YoY to RMB18.6 billion, driven by RMB5.9 billion in licensing income. Excluding licensing income, finished drug sales increased 11% YoY to RMB10.2 billi......

BofAS issued a report saying that CSPC PHARMA (01093.HK)'s total revenue/ net profit attributable for 1H26 rose 40.1%/ 139.2% YoY to RMB18.6 billion/ RMB6.1 billion respectively. In 2Q alone, total revenue increased 93.8% YoY to RMB12.1 billion. Net profit attributable surged 389.3% YoY to RMB5.2 billion.The broker raised its 20......

M Stanley issued a report stating that after CSPC PHARMA (01093.HK)'s 2Q results, it updated its model. EPS estimates for 2026, 2027 and 2028 were raised by 10%, 11% and 10%, respectively, mainly reflecting faster collection progress of business development revenue and observed revenue recognition trends. At the same time, it al......